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Background: MMP-13 recognizes poorly-
defined sequences in collagens. 
Results: MMP-13 binds key residues in the 
canonical cleavage site and another site near the 
collagen N-terminus. 
Conclusion: MMP-1 and MMP-13 differ in 
their recognition and cleavage of collagen, 
which is regulated primarily through the Hpx 
domain of MMP-13. 
Significance: Our data explain the preference of 
MMP-13 for collagen II.  
 
Remodeling of collagen by matrix 
metalloproteinases (MMPs) is crucial to tissue 
homeostasis and repair.  MMP-13 is a 
collagenase with a substrate preference for 
collagen II over collagens I and III.  It 
recognizes a specific, well-known site in the 
tropocollagen molecule where its binding 
locally perturbs the triple helix, allowing the 
catalytic domain of the active enzyme to 
cleave the collagen α chains sequentially, at 
Gly
775
-Leu
776
 in collagen II.  However, the 
specific residues upon which collagen 
recognition depends within and surrounding 
this locus have not been systematically 
mapped.  Using our triple-helical peptide 
Collagen Toolkit libraries in solid-phase 
binding assays, we found that MMP-13 shows 
little affinity for Collagen Toolkit III, but 
binds selectively to two triple-helical peptides 
of Toolkit II.  We have identified the residues 
required for the adhesion of both proMMP-
13 and MMP-13 to one of these, Toolkit 
peptide II-44, which contains the canonical 
collagenase cleavage site (at helix residues 
775-6).  MMP-13 was unable to bind to a 
linear peptide of the same sequence as II-44.  
We also discovered a second binding site near 
the N-terminus of collagen II (starting at helix 
residue 127) in Toolkit peptide II-8.  The 
pattern of binding of the free hemopexin 
domain of MMP-13 was similar to that of the 
full-length enzyme, but the free catalytic 
subunit bound none of our peptides. The 
susceptibility of Toolkit peptides to 
proteolysis in solution was independent of the 
very specific recognition of immobilized 
peptides by MMP-13; the enzyme proved able 
to cleave a range of dissolved collagen 
peptides.  
Sequence requirements within collagen II for recognition by MMP-13 
2 
 
 Collagens are comprised of three α 
chains containing repeating Gly-X-X' triplets 
(where X and X' are often Pro and Hyp 
respectively).  This primary structure allows the 
formation of a right-handed collagen superhelix 
which endows the molecule with resistance to 
degradation by most proteases.  The fibrillar 
collagens I, II and III contain a conserved triple-
helical COL domain of 1014 residues, with 
short, non-helical extensions at each end, which 
constitutes a tropocollagen molecule.  Such 
collagens assemble side-by-side to form a three-
dimensional staggered array (a fibril) with a 
regular offset of 234 residues (one D-period) 
between adjacent tropocollagens.  This 
organization gives rise to the striated structure of 
the collagen fiber observed by transmission 
electron microscopy, where the 67 nm 
periodicity reflects the dimensions of one D-
period(1).  
 Collagenolytic MMPs are members of 
the zinc-dependent peptidase family whose 
tightly-regulated proteolytic activities play a 
pivotal role in extracellular matrix homeostasis, 
cell migration and wound healing. Under 
pathological conditions, uncontrolled tissue 
remodeling by collagenases such as MMP-13 is 
associated with the potentiation of tumor 
progression and metastasis, atherosclerotic 
plaque remodeling and arthritic disease(2).  The 
preferred substrate for MMP-13 is collagen II 
which is cleaved five times faster than collagen I 
and six times faster than collagen III(3), and 
more readily by MMP-13 than by other 
collagenases.   
 As with other MMPs, collagenases are 
secreted as pro-enzymes with an organized 
domain structure comprising a pro-peptide 
region (cleaved to yield the active mature 
enzyme), a globular, Zn
2+
-binding catalytic 
domain (Cat), a linker region and a C-terminal 4-
bladed -propeller hemopexin-like domain 
(Hpx)(4,5). The Cat and Hpx are thought to 
cooperate to recognize and bind to the cleavage 
site, in collagen D-period 4 (D4), three-quarters 
of the way along the tropocollagen 
molecule(6,7).  Binding of the Hpx is considered 
to facilitate local relaxation of the helix, 
allowing the Cat domain of the MMP to 
hydrolyze specific Gly-X bonds within Gly-X-
X', where X is either Leu or Ile, and X' is either 
Ala or Leu (i.e., within the triplet G-[I/L]-
[A/L])(8).  Deletion of the Hpx domain therefore 
results in a loss of collagenase activity(9,10). To 
date, two cleavage sites have been identified for 
MMP-13 within collagen II.  The first at Gly
775
-
Leu
776 
(numbering refers to position within 
collagen II helical domain) 
 
is shared by MMPs-
1 and -8; the second site, Gly
778
-Gln
779
(11) is 
three amino acids from the N-terminus of the 
newly-cleaved quarter fragment(12).  Several G-
[I/L]-[A/L] triplets are present in native 
collagen, indicating that, in principle, other 
scissile bonds may exist.  However, with the 
exception of MMP-13, most MMPs primarily 
cleave the collagen helix at a single location, 
reflecting the importance of the unique sequence 
which surrounds the cleavage site(13,14).   
 To simplify structural research, a mutant 
species, MMP-13(E204A), has been produced.  
The mutation lies within the active site, and 
MMP-13(E204A) lacks catalytic activity whilst 
retaining the same conformation.  The specific 
collagen residues required for recognition of the 
collagen triple helix and the residues 
within/surrounding the canonical collagenase 
site described above have not yet been 
systematically identified, and with this in view, 
we have investigated both wild type MMP-13 
and MMP-13(E204A) in the present study.  The 
use of both wild type and mutant active forms, 
together with their corresponding pro-forms and 
a free Hpx domain allows us to investigate the 
contribution to binding of all three component 
domains. 
 To facilitate mapping studies we 
synthesized a library of overlapping 
homotrimeric host-guest peptides, in which 27 
residues of primary collagen (guest) sequence is 
placed between [GPP]5 hosts that ensure triple-
helical conformation.  The last nine guest amino 
acids are the same as the first nine amino acids  
in each successive peptide, and these peptide 
libraries (referred to as Collagen II and III 
Toolkits respectively) encompass the entire 
triple helical domains of collagens II and 
III(15,16), reviewed by Farndale et al.(17).  
Here, we used these Toolkits to map MMP-13 
binding to collagens II and III, and we proceeded 
to synthesize subsidiary peptides to identify 
those residues surrounding the cleavage site that 
are required for the binding of MMP-13.  This 
systematic approach has also allowed us to 
identify a new MMP-13 binding site on collagen 
type II. 
 The recent elucidation(7) of the structure 
of MMP-1 in complex with a triple-helical 
peptide derived from the use of the Toolkits 
allows us to compare the binding activity of both 
collagenases to their common cleavage site, and 
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to show that there are marked differences 
between the binding activities of the two 
enzymes that may account for their differing 
specificities for collagens I, II and III. 
 
EXPERIMENTAL PROCEDURES 
 MMP-13 expression, purification and 
activation–Recombinant proMMP-13 was 
expressed and purified as previously 
described(18).  Where required, proMMP-13 
was activated to yield MMP-13 by incubation in 
1 mM 4-amino-phenylmercuric acetate (APMA) 
for 1 h at 37 °C. ProMMP-13(E204A) was 
expressed in E. coli BL21(DE3), refolded, 
purified, and activated essentially as described 
for proMMP-1(E200A)(19,20).  The Cat domain 
of MMP-13 (249-451) was expressed and 
purified from NSO mouse myeloma cells as 
previously described(12). MMP-13 GST-Hpx 
domain was expressed in E. coli using the 
pGEX-2T expression vector, the forward primer 
TCCGCGTGGATCCCTCTATGGTCCAGGAG
ATGAA and the reverse primer GCAA-
ATTCCATTTTGTGGTGTTGAAGAATTCAT, 
which contain BamHI and EcoRI restriction sites 
respectively, as previously described(16). 
 Peptide Synthesis–Collagen Toolkit II 
and III and other peptides were generated using 
an AB Systems Pioneer automated synthesizer 
and N-(9-fluorenyl)methoxycarbonyl (Fmoc) 
chemistry as previously described(15,16).  All 
peptides were verified using MALDI-TOF mass 
spectrometry and their triple-helical 
conformation confirmed by polarimetry. 
 Peptide Design–Unless stated otherwise, 
all peptides were triple-helical, a structure 
maintained by the flanking sequences, 
GPC(GPP)5- and -(GPP)5-GPC-amide, at their 
N- and C-terminus respectively.  For simplicity, 
peptides are referred to by their specific guest 
sequence.  A negative control peptide, (GPC-
(GPP)10-GPC-amide) is referred to as GPP10.  A 
linear version of Toolkit peptide II-44 contained 
the same guest sequence between disordered 
flanking host sequences, thus: 
GCPP(GPPP)2GGPPPG– II-44 guest sequence –
P(GPPP)2GGPPPGCPG-amide. 
 MMP-13 Toolkit Solid-Phase Binding 
Assays (SPBA)–Immulon 2 HB 96-well plates 
(Nunc, Langenselbold, Germany) were coated 
with Collagen Toolkit or other peptides, fibrillar 
or monomeric collagen at a saturating 
concentration (10 µg/ml in 0.01 M acetic acid) 
overnight at 4 °C. Fibrous bovine type I collagen 
was a gift from Ethicon Corporation 
(Somerville, NJ).  Monomeric collagen was 
obtained from Devro (Bathurst, Australia).  All 
further incubations were performed at room 
temperature, 24 °C, for 1 h unless otherwise 
stated.  The wells were washed three times with 
adhesion buffer (1 mg/ml BSA in Tris-Buffered 
Saline (TBS) containing 0.1 % (v/v) Tween-20) 
between each incubation step.  The wells were 
then blocked with 50 mg/ml BSA in TBS prior 
to the addition of MMP at a concentration of 83 
nM (unless otherwise stated) in adhesion buffer.  
Where indicated, increasing amounts of Toolkit 
peptides II-8 and II-44 were pre-incubated for 20 
min with the MMP prior to adhesion assays.  
Rabbit anti-MMP-13, raised against MMP-13 
hinge region (Abcam, Cambridge, UK), and goat 
anti-rabbit HRP (Dako, Ely, UK) were added at 
a dilution of 1:2000 in adhesion buffer prior to 
the addition of TMB substrate system (Sigma) 
and the plates read at 450 nm.  Rabbit HRP-
linked anti-GST (GE Healthcare; dilution 
1:10,000) was used to detect GST-Hpx.  To 
confirm affinity of the anti-hinge antibody for 
MMP-13 and MMP-13(E204A), increasing 
concentrations of MMP were coated onto an 
ELISA plate prior to blocking and detected as 
previously described. Binding curves were fitted 
using Prism 5.0 software (GraphPad, San Diego, 
USA), allowing total binding (Bmax) and 
equilibrium dissociation constant (KD) to be 
determined. 
 Biotinylation of MMP-13(E204A) and 
the Cat domain–Proteins were C-terminally 
biotinylated using an EZ-Link Micro Sulfo-
NHS-Biotinylation Kit (Pierce) according to the 
manufacturer’s instructions.  Successful biotinyl-
ation was detected via Western Blotting using an 
ultrasensitive Streptavidin-Peroxidase Polymer 
(Sigma). 
 Peptide digestion assays–To determine 
the likelihood of Toolkit peptide clipping by 
MMP-13 during SPBA experiments, Toolkit 
peptides at a final concentration of 80 mM were 
incubated with a high (4.4 µM final) 
concentration of MMP-13, MMP-13(E204A) or 
the equivalent volume of Tris buffer pH 7.4 for 1 
h at room temperature.  Proteolytic activity of 
MMP-13 was assessed following incubation of 
Toolkit peptides with 250 nM MMP for 16 h at 
24 °C and 37 °C respectively.  The samples were 
then either examined by electrophoresis under 
reducing conditions, with silver staining, or 
submitted for MALDI mass spectrometry.  SDS-
PAGE electrophoresis was performed on 4-12 % 
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NuPage® bis-tris gels (Invitrogen) according to 
the manufacturer’s instructions. 
 Mass Spectrometry Analysis–Peptides in 
TBS buffer, pH 7.4, were reduced with 5 mM 
tris(2-carboxyethyl)phosphine (Thermo 
Scientific-Pierce) for 10 min at 35 °C and then 
desalted using uC18ZipTips (Millipore) 
equilibrated and washed with 5 % (v/v) acetic 
acid.  Peptides were eluted with 2 l ferulic acid 
matrix (Sigma; 10 mg/ml in 50 % (v/v) aqueous 
acetonitrile), spotted to the MALDI target plate, 
dried and washed once with 2 l 5 % (v/v) acetic 
acid.  Mass spectra were collected on a MALDI 
MicroMX Instrument (Waters, UK) in reflectron 
mode at threshold laser power.  Spectra were 
calibrated externally with polyethyleneglycol 
1000-2000-3000 (Sigma) and then adjusted by 
lockmass to one of two known peptides present 
in all samples from the autodigestion of MMP-
13 (20-42 & 21-42, confirmed by ms/ms as 
below).  Mass accuracies were generally better 
than 20 ppm, allowing only a single 
interpretation of the cleavage site for most 
peptides.  Any ambiguities were resolved by 
ms/ms fragmentation on a separately desalted 
sample, eluted in 70 % MeOH/ 0.2 % (v/v) 
formic acid and analyzed on a Thermo LCQ 
Classic ion-trap instrument using static 
nanospray delivery.  This confirmed the 
sequence identity. 
 
RESULTS 
 Binding of MMP-13 to Toolkit peptides 
and collagen–Using SPBA we show that wild 
type MMP-13, in both its active and pro-enzyme 
form, bound prominently to just two peptides, II-
44 and II-8, with trace binding activity to peptide 
II-7 (Figure 1A). Binding of MMP-13 to II-44 
was slightly stronger than to II-8 with A450 
values of 0.7 and 0.6 respectively. Toolkit III 
showed uniform absence of binding (data not 
shown), consistent with the greater activity of 
the enzyme against collagen II(18).  Fibrous 
collagen I bound wild type MMP-13 strongly 
(A450 ≥ 1.0), whilst control peptides and 
uncoated wells showed the expected low 
reactivity (A450 ≤ 0.1).  Using wild type, MMP-
13 exhibited lower binding than proMMP-13 to 
Toolkit peptides. 
 MMP-13(E204A) and proMMP-
13(E204A) also bound Toolkit II, with II-44 and 
II-8 clearly resolved, again with slight, 
significant binding to II-7.  MMP-13(E204A) 
was less selective than proMMP-13(E204A), 
binding several other peptides (II-13, II-17, II-
21, II-45 and II-49 to II-56, with A450 ≥ 0.3; 
Figure 1B).  ProMMP-13(E204A) was 
constitutively less active overall.  This rank 
order of binding contrasts with that of the wild 
type enzyme, where the converse applied.  
MMP-13(E204A), but not proMMP-13(E204A), 
displayed higher background binding (A450 ≤ 
0.3) on Toolkit III and bound to several peptides, 
including III-44 that contains the canonical 
cleavage site, with low to intermediate affinity 
(A450 0.2- 0.8; data not shown). 
 This may suggest that the Cat, which 
contains the disabling Ala substitution, helps to 
define binding specificity.  Lower binding of 
proMMP-13(E204A) might suggest that 
obstruction by the pro-domain restricts access of 
collagen to the enzyme, diminishing but not 
abolishing its ability to bind.  The lower 
apparent binding of the active wild type MMP-
13 might be due either to inhibition of binding 
by residual pro-domain peptides, as previously 
observed(21,22) or by autolysis, effects that 
appear to predominate in the active enzyme. 
 Binding affinity to II-44 and II-8–We 
applied increasing concentrations of the MMP 
preparations to peptides II-8 and II-44 to 
compare binding affinities using SPBA.  The 
linear peptide equivalent to II-44 supported 
negligible binding of any MMP-13 preparation 
(data not shown), contrasting with the ability of 
a similar peptide(23,24) to support the binding 
of fibronectin, which recognizes the same 
site(25,26).  Comparison of the pro-forms of the 
enzyme on both triple-helical peptides suggests 
broadly similar affinities (p = 0.37), with KD 
ranging from 130 to 380 nM, the latter figure 
(the only outlying value) being the estimate for 
proMMP-13(E204A) binding to peptide II-8  
(data not shown). 
 Our Toolkit and SPBA data indicate that 
both the pro and active forms of MMP-13 bind 
more strongly to II-44 than II-8.  To investigate 
the relative affinities of these interactions, we 
pre-incubated MMP-13(E204A) with II-8 and II-
44 ranging from 0.5 to 50 µg/ml and then 
measured binding in SPBA to the same 
immobilized peptides.  Consistent with the data 
above, each peptide in solution blocked MMP-
13(E204A) adhesion to its own immobilized 
form (Figure 2A), with II-44 showing IC50 ~8 
µg/ml, and II-8 about a four-fold weaker 
inhibition.  II-8 caused very slight inhibition of 
adhesion to II-44 at up to 50 µg/ml (extrapolated 
IC50 ~ 150 µg/ml) whilst II-44 was a potent 
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inhibitor of binding to II-8 (IC50 < 0.5 µg/ml).  
These data confirm II-44 as a more potent ligand 
for MMP-13 than II-8 (p = 0.017, Kruskal-
Wallis test).  
 It was noted that Bmax was dependent on 
the presence of the active site mutation, being 
roughly double in the proMMP-13(E204A) and 
MMP-13(E204A) mutant forms compared with 
their wild type counterparts (p < 0.02, 2-way 
ANOVA, Figure 2B).  This was not due to 
different recognition of wild type and MMP-
13(E204A) by the detecting antibody (data not 
shown).  
 Binding to full-length collagen I–Active 
forms of MMP-13 and MMP-13(E204A) were 
used in similar assays to establish the ability of 
the enzyme to bind fibrillar and monomeric 
collagens (Figure 3).  Both enzyme preparations 
exhibited much lower binding to saturated 
coatings of monomeric collagen I than to II-44. 
This may reflect the lower density of binding 
sites in monomeric collagen, where there are two 
sites per 1000 residues, compared with one site 
per 63 residues in these Toolkit peptides.  The 
two substrates are directly comparable, since 
rotary shadowing/transmission electron 
microscopy (27) suggests that monomeric 
collagens lie flat upon a surface, as would also 
be anticipated for the much shorter Toolkit 
peptides.   
 Our data suggest that the binding of the 
MMP to collagen is greatly facilitated by 
fibrillar conformation (KD ~ 40 nM).  Pugh et al. 
have shown that collagen fibers as used here 
form a complex meshwork that extends tens of 
microns above the coated surface(28), offering a 
large binding area.  The observed higher affinity 
implies co-operative binding to discrete sites 
within the fiber network.  Possibly, a new 
composite binding site comprising the canonical 
site and sequences in the adjacent tropocollagen 
molecules within a single fiber might also 
generate a larger footprint on the fiber surface, 
and hence higher affinity.   
 Binding of Cat and Hpx Toolkit peptides 
II-8 and II-44–To determine whether the MMP-
13 Cat and Hpx domains were individually able 
to recognize Toolkit peptides, their binding was 
assessed in SPBA.  Though the Cat domain was 
able to recognize collagen, it was unable to bind 
to any Toolkit II peptides (data not shown), 
whilst Hpx bound well to peptide II-44 (A450  
0.8) and weakly to II-8 (A450  0.2; Figure 1C).  
Both domains bound fibrillar collagen I, albeit 
weakly in the case of the Cat domain.  
 Ala-scanning of II-44–To explore the 
primary sequence determinants of MMP-13 
binding to II-44 in SPBA, we made a set of 
truncated and alanine-substituted ('Ala-scanned') 
triple-helical peptides of the same general host-
guest form.  The data are shown in Figure 4.  
MMP-13(E204A), and to a lesser extent wild-
type MMP preparations, proMMP-13(E204A) 
and Hpx were supported by an 18-residue triple-
helical peptide, II-44A, which lacked only the 
three C-terminal triplets of II-44. Peptide 44B, 
containing only these missing triplets, 
GFOGLOGPS, supported no binding.  
Successive omissions of triplets (peptides II-44C 
to II-44I) from both the N- and C-terminus of II-
44A each modulated the binding of MMP-
13(E204A), indicating that further truncation 
was inappropriate.  These findings were used to 
define the C-terminus of the Ala-scanned 
sequence, culminating in the addition of a 
single-triplet native sequence extension, GPQ, to 
the N-terminal boundary of II-44, thus creating a 
21-residue peptide (44J).  Using the 
nomenclature of Schechter and Berger to define 
the distance from the cleavage site, peptide 44J, 
GPQG~LAGQRGIVGLOGQRGER, stretched 
from P4 to P17' where P1, preceding the scissile 
bond, is the first (Gly) residue of the guest 
sequence of peptide II-44.  
 As with II-44, binding to 44J differed 
amongst MMP-13 preparations, with MMP-
13(E204A) binding most strongly (A450  0.8), 
then proMMP-13, then proMMP-13(E204A), 
then active MMP-13, and lastly the Hpx domain 
alone (A450  0.4).  All MMP-13 preparations 
yielded data that allowed us to discriminate 
between the Ala-substituted peptides.  
 Three residues were uniformly essential 
for binding, P8'(V), P14'(R) and P17'(R).  No other 
Ala-substitutions perturbed the binding of MMP-
13(E204A), consistent with less rigorous 
determinants of peptide binding to this mutant 
form, but several residues were important for the 
binding of the other MMP preparations 
including the Hpx domain.  P4'(Q), P5'(R), 
P10'(L), and P11'(O) all fall into this category, 
whilst P1'(L) was similarly important for the 
binding of Hpx, and to a lesser extent MMP-13 
and proMMP-13(E204A). 
 Two residues in particular in the parent 
peptide, P13'(Gln) and P16'(Glu), appeared to 
exert a restrictive effect, since MMP-13 binding 
increased after Ala-substitution.  Further 
residues, P3(Pro), P2(Gln) and P7'(Ile), showed a 
similar tendency with some but not all MMP-13 
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preparations.  These data suggest that 
recognition of the native sequence is poised 
between firm binding and release of the enzyme, 
perhaps allowing some freedom to re-organize 
or to permit relaxation of the triple-helical 
structure prior to cleavage, or to ensure release 
of the enzyme once the substrate is cleaved. 
 Like the intact forms of the enzyme, 
Hpx only bound to Toolkit peptides II-8 and II-
44 in the static adhesion assays (Figure 1C). The 
adhesion profile of the Hpx domain to II-44 Ala-
scanned peptides reflected that of the intact 
enzyme(s), indicating that it is primarily the Hpx 
domain which defines the recognition of the 
intact enzyme to the collagenase cleavage site of 
collagen II. 
 Proteolysis of Toolkit peptides–We first 
considered the possibility that poor binding of 
active MMP-13 to peptides or collagen might 
reflect proteolysis and release from the 96-well 
surface during SPBA, leading to loss of apparent 
binding activity.  Our binding data also 
suggested that peptide II-8 may offer a novel 
cleavage site for MMP-13.  We therefore 
investigated the ability of MMP-13 to cleave 
several triple-helical peptides, selected by their 
differing ability to bind MMP-13(E204A).  
Peptides II-44 and II-8 (high-affinity), III-5 and 
III-40 (intermediate affinity) and II-24 and II-28 
(non-binding), were incubated with a high 
concentration (4.4 µM) MMP-13 for 1 h at 24 
°C, as in our adhesion assays, then examined 
using SDS gel electrophoresis as described.  The 
migration of the peptides was slower than their 
mass would suggest, an observation which is 
well known. The actual masses of the peptides 
are shown in Table 1.  No proteolysis of any 
Toolkit peptide was observable after 1 h at 24 °C 
(data not shown), despite the rather high enzyme 
concentration used, allowing us to conclude that 
our binding assays were not compromised by 
substrate degradation.  As expected, MMP-
13(E204A) (and buffer control) proved unable to 
degrade any peptide under any condition tested 
in the present study. 
 However, following incubation of the 
peptides with 250 nM MMP-13 for 16 h at 24 
°C, a temperature at which the majority of each 
peptide is folded as a triple helix, proteolysis of 
II-8, II-44, II-24 and III-5 was detectable by 
mass spectrometry.  Cleavage sites are shown in 
Table 1.  Degradation was slight and not 
detectable using SDS-PAGE (Figure 5A).  At 37 
°C, proteolysis was clearly observable by SDS-
PAGE for all peptides tested (Figure 5B).  
Cleavage sites were subsequently confirmed by 
MALDI mass spectrometry (Table 1).  At 24 °C, 
peptide II-44 was specifically cleaved at both its 
primary and secondary collagenase cleavage 
sites (GL and GQ respectively).  Peptide II-8 
was cleaved, but at a G~A bond downstream 
from the expected GL cleavage site. At 37 °C 
however, the degradation of II-44 was 
increasingly marked and less specific, most 
likely due to the gelatinase activity of MMP-13. 
 
DISCUSSION 
 We used four full-length MMP-13 
preparations to screen the Toolkit peptides; the 
wild type pro-form expressed and purified from 
mouse myeloma cells, and recombinant MMP-
13(E204A) and proMMP-13(E204A) expressed 
in pET3 cells as previously described (18,20).  
The active wild type MMP-13 was prepared by 
APMA-induced cleavage of its pro-form (18,29).  
In addition, we tested the binding properties of 
recombinant Cat and Hpx domains.  The present 
work shows that collagen and two triple-helical 
Toolkit peptides, II-44 and II-8, support firm 
adhesion of MMP-13 in both its active and pro- 
forms, and of the equivalent catalytically 
inactive mutant forms, proMMP-13(E204A) and 
MMP-13(E204A).  Cat bound weakly to 
collagen, but not to any Toolkit peptide, whilst 
Hpx bound to II-8 and to a greater extent II-44, 
much like proMMP-13(E204A).   
 The fidelity of MMP-13(E204A) 
substrate recognition–The use of MMPs that are 
alanine-substituted at the catalytic site simplifies 
structural and binding studies, since both 
autolysis and digestion of adhesive substrates are 
avoided.  Here, we observe differences in 
behaviour of the active conformation of MMP-
13(E204A) compared with either its own pro-
form or both the active or pro-forms of the wild 
type enzyme.  We find MMP-13(E204A) to bind 
less specifically to Toolkits, with extra hits 
observed in Toolkit II and a noisy pattern of 
binding to Toolkit III.  MMP-13(E204A) was 
less sensitive to Ala-scanning of peptide II-44, 
notably at P5', P10' and P11'.  In contrast, pro-
MMP-13(E204A) behaved exactly as pro- or 
active wild type.  We also found a two-fold 
higher Bmax for MMP-13(E204A), which implies 
twice the number of molecules binding per 
peptide.  In turn, this observation suggests 
dimerisation in situ, the first immobilized copy 
of MMP-13(E204A) recruiting a second 
molecule, a process mediated by interactions 
remote from the peptide-binding surface of the 
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enzyme. Crystallographic analysis by Stura et 
al.(30) indicates close agreement between the 
structures of native and mutant forms, but they 
also report MMP-13(E204A) to be monomeric 
in solution despite observing dimerization in 
their crystal structure, mediated by the Hpx 
domain.  Reconciling these findings suggests 
that the E204A substitution subtly modulates the 
relationship between the Cat and Hpx domains 
in the active conformation of the enzyme, in a 
way that renders the Hpx less selective in 
recognising collagenous substrates. 
 Collagen residues critical for 
recognition by MMP-13–Binding of MMP-13 to 
peptide II-44 was expected, since it contains the 
known collagenase cleavage site near the N-
terminus of collagen D-period 4, whereas the 
prominent but lower affinity of MMP-13 for II-8 
was unsuspected; its sequence occurring in the 
centre of D-period 1 (see Figure 6).  Equilibrium 
binding studies suggest similar affinities of all 
the MMP forms tested for II-44, with KD on the 
order of 200-400 nM.  Ala-scanning of 44J, a 
shorter peptide derived from II-44, revealed 
several residues that make important 
contributions to the binding of MMP-13, i.e. that 
Ala-substitution diminishes binding.  Five of 
these lie within the C-terminal half of the guest 
sequence of the peptide, P8'(V), P10'(L), P11'(O), 
P14'(R) and P17'(R).  Conversely, substitution of 
two further residues in this region P13'(Q) and 
P16'(E) enhanced the binding of all MMP-13 
preparations.  These observations underline the 
importance of this tract of the peptide in 
securing MMP-13 binding, and clarify the basis 
for its interaction with peptide II-8.  II-8 shares 
just three critical residues with II-44, 
corresponding to P1'(L), P5'(R) and P17'(R), but in 
addition, contains two alanine residues, 
corresponding to P13' and P16'.  Ala-substitution 
of both residues in peptide II-44J enhanced 
MMP-13 binding.  Good binding of II-8, 
especially in the region predicted to bind Hpx, 
might therefore be anticipated.   
 The importance of Hpx in MMP–
collagen interaction–The distance of many of 
these residues from P1~P1' suggests that the Hpx 
domain is the main contributor to MMP-13 
binding, investigated further using isolated Hpx 
which bound to both II-8 and II-44, exactly 
echoing the adhesion profile of proMMP-
13(E204A) on the Ala-scanned peptide set 
(Figure 4).  These data suggest a second site of 
interaction for Hpx in II-44.  In the first, 
“productive” mode of binding, Hpx engages 
residues P10' to P17', GLOGQRGER, which 
would align the scissile P1~P1' (G~L) bond close 
to the catalytic site.  The inhibition of Hpx 
binding by Ala-scanning at P1', P4' and P5' 
indicates that these conserved residues, 
G~LAGQRGIV, can also interact directly with 
the Hpx domain, offering a second locus that can 
recruit MMP-13 to the environs of its site of 
action. In this case however, alignment of the 
Cat with P10–P9 would not be productive, as the 
proline-rich collagen sequence at this location 
would restrict local unwinding by the MMP-13 
enzyme.  
 Comparison of MMP-13 with MMP-1–
Our interpretation is informed by the crystal 
structure of the complex between MMP-1 and a 
triple-helical peptide derived from II-44J.  
Inspection of the MMP-1–peptide co-crystal 
shows that P8' and P10' interact with the proximal 
rim of the Hpx -propeller, binding to the 
interface between blades 1 and 2, with the distal 
rim of Hpx tilted away from the axis of the 
peptide.  No interactions were observed beyond 
P11'. Only two peptide residues, P1'(L) and 
P10'(L), had measurable effects on binding of 
MMP-1 using a very similar SPBA, whilst 
effects of substitutions distal to P10' were 
negligible.  In contrast, using MMP-13, there 
were obvious effects of Ala-substitutions from 
P10'(L) to P17'(R), suggesting that its Hpx enjoys 
a closer interaction with regions of the peptide 
extending further away from the scissile G~L 
bond. 
 Another marked difference between the 
two enzymes is that proMMP-1 did not bind to 
collagen or Toolkit peptides, with the pro-
domain apparently impeding access to the Cat 
(7,31), preventing the critical P1' interaction with 
substrate.  How can MMP-13 avoid this 
constraint?  Superposition of the Cat domains 
from the crystal structures of full-length MMP-1 
and MMP-13 by Stura et al. illustrates the 
different Cat–Hpx interface in the two enzymes.  
The two domains move closer together in MMP-
13, with Hpx rotated relative to Cat by 30°.  
The effect is to move the collagen-binding S10' 
pocket of MMP-13 by about 7 Å relative to that 
of MMP-1(22).  This might facilitate collagen–
proMMP-13 binding without displacement of 
pro-domain from the S1' site.  Like MMP-13, 
both proMMP-3 and proMMP-9 can bind 
collagen (32).  Alternatively, although activation 
of MMPs is achieved through proteolytic 
cleavage, interaction with substrate may also 
displace the pro-domain from the active center 
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of the enzyme(33).  Nonetheless, our SPBA data 
suggests that the pro-domain does impede 
collagen binding to some degree:  whilst the two 
full-length pro-forms of MMP-13 showed 
similar binding, the catalytically dead MMP-
13(E204A), lacking pro-domain, showed highest 
binding to Toolkit peptides.   
 The significance of the II-8 binding site–
The presence of this site was not expected, and 
its potential as a substrate for the collagenase 
activity of MMP-13 appears restricted to the 
G~A clip observed at 24 °C.  It is located at the 
centre of II-8, four triplets C-terminal to the 
more promising GLOGER motif that aligns well 
with the canonical site in II-44; both sites occur 
at the start of the guest sequence in their 
respective peptides, and in nature, P4 to P1 are 
GPRG and GPQG respectively.  Q, preceding 
the canonical (II-44) site, is well represented at 
P2 in the MEROPS database(34), whilst R, 
preceding the optimally aligned II-8 site, occurs 
just 4 times in 41 observations of MMP-13 
activity against collagenous substrates.  This 
locus in II-8 was clipped at 37 °C, and should 
not be discounted as an authentic site for the 
collagenolytic activity of MMP-13.   
 The two sites may cooperate in 
recruiting MMP-13 to collagen.  In 2007, 
Overall and Butler(20) proposed an "inchworm" 
model of MMP translation along the collagen 
molecule, based on the "burnt bridges" 
molecular ratchet model (for MMP-1) of 
Saffarian et al.(33), and the atomic force study 
of Rosenblum et al.(34) on MMP-9.  For this 
model to be generally applicable, the MMPs 
would need to have affinity for long stretches of 
sequence within the collagen helix, as well as the 
capacity for sequence-independent cleavage of 
triple-helical collagen.  Manka et al.(6) found 
that MMP-1 lacked the ability to bind well to 
any site other than II-44 in collagen II, and we 
show here that MMP-13 is only slightly less 
selective, binding to II-8 as well as to the second 
site in II-44.  The "inchworm" model may 
therefore have limited validity for MMP-13, 
applying to translocation of Hpx binding from 
the P1' to P5' tract to P10' to P17'.  The "quarter-
stagger" assembly of the collagen fiber dictates 
that any D-period is aligned side by side with all 
others (see figure 6).  Thus, a molecule that 
bound at the start of D1 would be quite close to 
the start of D2, D3, D4 and of the truncated D5 
(the gap region) in adjacent tropocollagen 
molecules.  The simple model of fiber assembly 
allows us to calculate the proximity of any two 
sites.  GLAGQR in II-44 represents residues 
775-780 of the tropocollagen helix, or 73-78 of 
the D-period, whereas GLOGER in II-8 is 
residues 127-132 of both the helix and D-period.  
Within a fiber, therefore, there is an axial offset 
of 54 residues between the two sites, 
corresponding to about 15 nm, close enough, 
perhaps, to support some co-operativity.  
Inspection of the co-crystal of MMP-1 and a II-
44-derived triple-helical peptide(7) suggests that 
an MMP can span about 25 collagen helix 
residues, less than 10 nm.  Although not 
contiguous, therefore, it is plausible that 
hydrolysis of the canonical site might lead to 
anchorage of MMP-13 by its Hpx domain to the 
clipped helix, with sufficient flexibility in the 
clipped collagen to relocate via its Cat to nearby 
II-8 sites.  This "ball and chain" model would 
also apply to adjacent canonical sites in D4.  The 
three-dimensional structure may be more 
complex than the simple model(35,36), but in 
either of these two, reciprocal, renderings of the 
fiber, hydrolysis at one site could reveal the 
other site beneath. 
 Finally, whether it is a cleavage site or 
not, it is plausible that II-8 fulfils a depot 
function, acting to sequester proMMP-13 in the 
collagen matrix to be activated as required. 
MMP-13 differs from MMP-1 in this respect, in 
that only the active form of MMP-1 was found 
to bind to Toolkit II(7). 
 The selectivity of MMP-13 for different 
collagens–Comparison of the collagenase 
cleavage sites of the various fibrillar collagens 
with the sequences of the MMP-13-binding 
peptides provides a basis for their relative 
recognition and subsequent cleavage.  High 
identity occurs between 1(I) and 1(II), with 
only two non-identical but conserved amino 
acids within the sequence equivalent to II-44.  
The reported 6-fold lower activity of MMP-13 
on collagen I may therefore reside in the 
different sequence at P4' and P5' in 2(I), where 
A and O occur in place of Q and R, both of 
which, when replaced with A in peptide II-44J, 
support reduced binding of active MMP-13.  In 
collagen III, only three (P5'(R), P11'(O) and 
P17'(R)) of the eight critical amino acids are 
identical with those in collagen II.  We therefore 
anticipate a lower affinity interaction of MMP-
13 with collagen III, consistent with its relative 
resistance to proteolysis.   
 Toolkit peptides as substrates for 
proteolysis by MMP-13–We tested the ability of 
MMP-13 to digest six peptides during 16 h at 
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either 24 °C or 37 °C by examining peptide 
fragments by mass spectrometry.  After 
incubation at 24 °C, we observed both expected 
clips in II-44, at P1~P1' and P3'~P4', at the 
canonical and secondary sites that are well-
known(12).  At this temperature, only five other 
clips were located in the six peptides tested, 
including a G~A bond in II-8.  We had 
anticipated that the G~L bond at the start of the 
guest sequence of II-8, equivalent to P1~P1' in II-
44, might be susceptible, best aligning with the 
catalytic site according to our interpretation of 
Ala-scan data, but it proved otherwise.  The 
MEROPS database(34) describes the preferred 
MMP-13 cleavage sequence as being 
GPxG~LxGx, with Proline (bold) occurring at 
P3 in 92 of 147 sites, P being the most abundant 
P3 residue in both collagenous and non-
collagenous substrates.  The sequence cleaved in 
II-8 conforms well, the site being GPAG~AA, 
with no other imino acids occurring within 9 
residues, which may contribute to a more 
relaxed structure that facilitates proteolysis(37).  
 At 37 °C, all Toolkit peptides tested 
were cleaved by MMP-13, irrespective of their 
ability to bind MMP-13(E204A) in SPBA, and 
20 different sites were identified in addition to 
the 7 found at 24 °C.  We found four cleaved 
G~L sites, from a total of ten occurrences of GL 
in the six peptides tested.  Five of these ten were 
within G~LO triplets, only one of which was 
cleaved, suggesting that the hydroxyproline at 
P2' confers a protective effect, which might 
account for the resistance of the GL bond in II-8 
to hydrolysis.  We also found four G~E sites, of 
only eight GEx' triplets within the peptides 
tested.  The MEROPS database(34) describes the 
preferred MMP-13 cleavage sequence as being 
GPxG~LxGx, with Proline (bold) occurring at 
P3 in 92 of 147 sites, P being the most abundant 
P3 residue in both collagenous and non-
collagenous substrates.  Deng et al. report that 
the hydrophobic MMP-13 S3 subsite has a 
preference for Pro in P3(38), and propose a 
consensus motif, PLG~MR.  Our limited data 
suggest a novel consensus sequence: PPG~ER, 
with POG~Ax' and POG~LA as alternatives.  
Our data concur with that compiled in 
MEROPS, although G~E cleavage is only 
recorded twice therein, as proline occurs as P3 in 
15 of the 27 cleavage sites (~55 %) we report 
here, regardless of temperature.  
 We considered why elevating 
temperature might increase the number of 
resolvable cleavage sites.  Firstly, reaction rates 
will increase, but secondly, our peptides have 
limited thermal stability, with melting 
temperatures typically of 45 °C.  Thus at 37 °C a 
substantial proportion (18-52 %), estimated for 
each specific peptide and shown in Table 1, 
exists in unfolded, single-stranded form(39) 
where, unlike native collagens, tertiary structure 
no longer governs substrate specificity and 
MMP-13 functions as a gelatinase(40).  
Digestion of any single-stranded material that is 
susceptible to proteolysis by MMP-13 will draw 
the equilibrium in favor of unfolded peptide, 
leading to gradual depletion of intact triple helix.  
Mass spectrometry revealed that few of the 
common peptide fragments were generated by 
cleavage within the GPP hosts.  This may reflect 
the greater thermal stability of the relatively 
proline-poor host sequence, which unfolds less 
readily and so presents a less frequent target for 
proteolysis by MMP-13 than the guest sequence.   
 In summary, here we show that, unlike 
MMP-1, both the pro- and active forms of 
MMP-13 are able to bind collagen, at both the 
canonical MMP cleavage site, and at a second, 
lower-affinity site located in Toolkit peptide II-8 
(corresponding to D-period 1 of the collagen 
monomer).  We show that the recognition of II-
44 by MMP-13 is primarily mediated by the Hpx 
domain and is specified by GLxGQR motifs at 
either P1 - P5' or P9' - P14'.  By examining the 
cleavage of selected collagen peptides by MMP-
13, we show that hydrolysis is not confined to 
motifs recognized by the Hpx domain, but is 
likely to include peptide strands that are 
unfolded at 37 °C.  These data provide a 
rationale for the structural regulation of collagen 
proteolysis and the resistance of peptide II-8 to 
cleavage by MMP-13 at 24 
o
C. 
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FIGURE LEGENDS 
 
Table 1. Mass analysis of degraded Toolkit peptides. Following degradation for 16 h at 24 °C 
and 37 °C as described for Figures 9B and C respectively, Toolkit peptides incubated with MMP-13 
or Tris buffer pH 7.4 (as a negative control) were subjected to MALDI mass spectrometric analysis to 
determine the peptide cleavage site(s) of MMP-13. Cleavage sites are summarized with the site of 
proteolysis after the first residue in the sequence of six. Triple helical abundance of each peptide at 37 
°C is also listed. 
 
Table 2. Summary of the effect of alanine substitution on MMP-13 binding. Residues of 
Toolkit peptide II-44J are listed as are the residues of MMP-1 that interact with these amino acids 
(MMP-1 residues in bold are conserved in MMP-13). The effect of alanine substitution of each 
residue is annotated as ND = Not done; [   ] residue lies upstream of guest sequence in peptide II-44J; 
– – –, – – Reduction of MMP-13 binding to peptide by   ≥ 50 %, and ≥ 25 % respectively; 0 = No 
observed change in MMP-13 adhesion to peptide; +, ++ Increase in MMP-13 binding of  25-0 % and  
≥ 25 % respectively; *Ala substitution that reduced MMP-1 adhesion relative to II-44J.  
 
Figure 1. Adhesion of MMP-13 preparations to Collagen II Toolkit peptides. Plates were coated 
with 10 µg/ml Toolkit II peptides, fibrillar type I collagen and the negative binding peptide GPP10. 
(A) proMMP-13 (black bars) and MMP-13 (grey bars), (B) proMMP-13(E204A; black bars) and 
MMP-13(E204A; grey bars), (C) Hpx at a concentration of 83 nM were allowed to adhere to the 
peptides for 1 h at room temperature. Full-length MMP-13 preparations were then detected using an 
antibody directed at the MMP-13 linker region, and Hpx with an anti-GST antibody as described in 
Experimental Procedures. Data represent mean A450 ± S.E. of four experiments.  For reference, 
collagen D-periods corresponding to these peptides are shown as grey bars below, and the collagenase 
cleavage site indicated by an arrow. 
 
Figure 2. (A) Competitive inhibition of MMP-13 adhesion to Toolkit peptides II-8 and II-44. 
(A) MMP-13 or MMP-13(E204A) were pre-incubated with increasing amounts of Toolkit peptides II-
8 and II-44 prior to adhesion assays on II-8 and II-44 respectively. Absorbance was measured at 450 
nm. Data represents the mean ± S.E. of four experiments. (B) The effect of MMP-13(E204A) 
mutation on increased proMMP-13 adhesion to Toolkit peptides II-8 and II-44. Binding of MMP-13 
and MMP-13(E204A) to collagen coated ELISA wells was performed as described in Figure 1. Both 
pro- and active forms of the enzyme exhibited broadly similar affinities (p = 0.37), with KD ranging 
from 130 to 380 nM, the latter figure (the only outlying value) being the estimate for proMMP-
13(E204A) binding to peptide II-8Data represents the mean ± S.E. of four experiments.  
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Figure 3. Binding of MMP-13 and MMP-13(E204A) to monomeric and fibrillar type I 
collagens. Binding of MMP-13 and MMP-13(E204A) to collagen coated ELISA wells was performed 
as described in Figure 1. For MMP-13 binding to fibres and monomers, KD values were 33 and 118 
nM, respectively, and for MMP-13(E204A), 52 and 26 nM, respectively. Data points represents the 
mean ± S.E. of four experiments, and differences were not significant.  
 
Figure 4. Adhesion of proMMP-13, MMP-13, proMMP-13(E204A), MMP-13(E204A) and the 
Hpx domain to II-44 variant Toolkit peptides was carried out as described for Figure 1. The dashed 
line represents MMP adhesion level on peptide II-44J, and the solid line MMP baseline adhesion on 
peptide II-44B. Data represents the mean ± S.E. of four experiments.  
 
Figure 5. Analysis of possible degradation of Toolkit peptides by active MMP-13. Toolkit 
peptides at a final concentration of 1200 µg/ml to which MMP-13(E204A) displayed high binding (II-
8 and II-44; A450 > 1.2); intermediate binding (Toolkit peptides III-5 and III-40; A450 0.5-0.8) and low 
binding (Toolkit peptides II-24 and II-28; A450 < 0.2) were incubated with Tris buffer, MMP-13 or 
MMP-13(E204A) at 250 nM final concentration were incubated at (A) 24 °C for 16 h and (B) 37 °C 
for 16 h. After incubation, samples were subjected to electrophoresis under reducing conditions and 
silver stained. Images are representative of three experiments. 
 
 Figure 6. Schematic illustration of a collagen fiber.  Above shows the alternating gap (pale) 
and overlap (dark) banding, derived from the staggered assembly of the fiber from tropocollagen 
molecules.  Middle, the "quarter stagger" between tropocollagen molecules is shown, with labeled D-
periods alternating (gray and white) with the MMP-13 binding sites mapped onto them (black).  
Below the linear separation between the II-44 and II-8 sites is shown, and their sequences provided.  
Key binding residues in II-44 and II-8 are larger, bold font, whilst restrictive residues (II-44) are 
smaller font.  Lateral separation between the axes of the tropcollagen monomers (not indicated) is of 
the order of 3 nm. 
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TABLE 1. MALDI MASS ANALYSIS OF DEGRADED TOOLKIT PEPTIDES. 
PEPTIDE 
AND MASS 
(Da) 
CLEAVAGE 
TEMP (oC) 
CLEAVAGE SITES (Indicated in black) 
% Triple 
Helical 
peptide at  
37 oC 
II-8 
5503 
 
24 
37 
GPCGPPGPPGPPGPPGPP-GLOGERGRTGPAGAAGARGNDGQOGPA-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GLOGERGRTGPAGAAGARGNDGQOGPA-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GLOGERGRTGPAGAAGARGNDGQOGPA-GPPGPPGPPGPPGPPGPC 
48 
II-44 
5705 
 
24 
37 
GPCGPPGPPGPPGPPGPP-GLAGQRGIVGLOGQRGERGFOGLOGPS-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GLAGQRGIVGLOGQRGERGFOGLOGPS-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GLAGQRGIVGLOGQRGERGFOGLOGPS-GPPGPPGPPGPPGPPGPC 
80 
II-24 
5536 
 
24 
37 
GPCGPPGPPGPPGPPGPP-GKAGEKGLOGAOGLRGLOGKDGETGAA-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GKAGEKGLOGAOGLRGLOGKDGETGAA-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GKAGEKGLOGAOGLRGLOGKDGETGAA-GPPGPPGPPGPPGPPGPC 
54 
II-28 
5638 
 
24 
37 
GPCGPPGPPGPPGPPGPP-GEAGAOGLVGPRGERGFOGERGSOGAQ-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GEAGAOGLVGPRGERGFOGERGSOGAQ-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GEAGAOGLVGPRGERGFOGERGSOGAQ-GPPGPPGPPGPPGPPGPC 
57 
III-5 
5728 
 
   24 
37 
GPCGPPGPPGPPGPPGPP-GERGLOGPOGIKGPAGIOGFOGMKGHR-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GERGLOGPOGIKGPAGIOGFOGMKGHR-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GERGLOGPOGIKGPAGIOGFOGMKGHR-GPPGPPGPPGPPGPPGPC 
82 
III-40 
5447 
 
24 
37 
GPCGPPGPPGPPGPPGPP-GAAGFOGARGLOGPOGSNGNOGPOGPS-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GAAGFOGARGLOGPOGSNGNOGPOGPS-GPPGPPGPPGPPGPPGPC 
GPCGPPGPPGPPGPPGPP-GAAGFOGARGLOGPOGSNGNOGPOGPS-GPPGPPGPPGPPGPPGPC 
58 
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TABLE 2. EFFECT OF ALANINE MUTATION ON MMP-13 BINDING 
 
Position 
Residue Effect of Ala 
substitution on 
MMP-13 binding 
Residues of MMP-1 in 
contact with peptide** 
 
[P5] 
P4 
P3 
P2 
P1 
P1' 
P2' 
P3' 
P4' 
P5' 
P6' 
P7' 
P8' 
P9' 
P10' 
 
P11' 
P12' 
P13' 
P14' 
P15' 
P16' 
P17' 
 
 
[O] 
G 
P 
Q 
G 
L* 
A 
G 
Q 
R 
G 
I 
V 
G 
L* 
 
O 
G 
Q 
R 
G 
E 
R 
 
 
[ND] 
ND 
0 
0 
ND 
– – 
ND 
ND 
– – – 
– – 
ND 
0 
– – – 
ND 
– – – 
 
– – – 
ND 
++ 
– – – 
ND 
+ 
– – 
 
 
[F166] 
 
N152, Q167 
S153, A163, H164 
N161 
A165, H203 
G160, H209 
 
N161, Y218, S220, Y221 
Y218, P219, S220 
 
E294, N296, V300, F301 
R285, V300, F301 
R285 
I271, E274, M276, R285,  
     F289, Y290, F301, W302 
R272, E274, Q335 
 
 
 
 
 
 
 
  
ND   Not done;  
[   ]   Residue lies upstream of guest sequence in peptide II-44J. 
– – –, – – Reduction of MMP-13 binding to peptide by   ≥50%, and ≥25% respectively. 
0   No observed change in MMP-13 adhesion to peptide. 
++, +  Increase in MMP-13 binding of    ≥25% and 25-0% respectively. 
*   Indicates Ala substitution that reduced MMP-1 adhesion relative to II-44J. 
**  Bold MMP-1 residues are conserved in MMP-13. 
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FIGURE 1. ADHESION OF MMP-13 PREPARATIONS AND Hpx TO TOOLKIT II  
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FIGURE 2. (A) COMPETITIVE INHIBITION OF MMP-13 ADHESION TO TOOLKIT PEPTIDES II-8 AND II-44 (B) THE EFFECT OF MMP-
13(E204A) MUTATION ON proMMP ADHESION TO II-8 AND II-44 
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FIGURE 3.  ADHESION OF MMP-13(E204A) AND MMP-13 TO TYPE I COLLAGEN MONOMERS AND FIBERS 
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FIGURE 4. MMP-13 ADHESION TO II-44 VARIANT PEPTIDES 
 
 
Peptide Name  Sequence                                                     MMP-13 BINDING (A450)  
pro-MMP-13                  MMP-13  proMMP-13(E204A)        MMP-13(E204A)  Hpx 
 
 
II-8    -----GLOGERGRTGPAGAAGARGNDGQOGPA 
II-44    -----GLAGQRGIVGLOGQRGERGFOGLOGPS  
44A    -----GLAGQRGIVGLOGQRGER--------- 
44B      -----------------------GFOGLOGPS   
44C      --------GQRGIVGLOGQRGER--------- 
44D      -----------GIVGLOGQRGER---------  
44E      -----GLAGQRGIVGLOGQR------------  
44F      -----GLAGQRGIVGLO---------------  
44G      --------GQRGIVGLO---------------  
44H    -----------GIVGLOGQR------------  
44I      --------------GLOGQRGERGFO------  
44J      --GPQGLAGQRGIVGLOGQRGER--------- 
P3A      --GAQGLAGQRGIVGLOGQRGER--------- 
P2A      --GPAGLAGQRGIVGLOGQRGER--------- 
P1’A     --GPQGAAGQRGIVGLOGQRGER--------- 
P4’A     --GPQGLAGARGIVGLOGQRGER--------- 
P5’A     --GPQGLAGQAGIVGLOGQRGER--------- 
P7’A     --GPQGLAGQRGAVGLOGQRGER--------- 
P8’A     --GPQGLAGQRGIAGLOGQRGER--------- 
P10’A    –-GPQGLAGQRGIVGAOGQRGER--------- 
P11’A    --GPQGLAGQRGIVGLAGQRGER--------- 
P13’A    --GPQGLAGQRGIVGLOGARGER--------- 
P14’A    --GPQGLAGQRGIVGLOGQAGER--------- 
P16’A    --GPQGLAGQRGIVGLOGQRGAR--------- 
P17’A    --GPQGLAGQRGIVGLOGQRGEA--------- 
 
 
 
  
0 0.2 0.4 0.6 0.8 1 1.2
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FIGURE 5. CLEAVAGE OF TRIPLE HELICAL TOOLKIT PEPTIDES BY MMP-13 16 h (A) at 24 °C, (B) at 37 °C 
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STRIATED COLLAGEN FIBER
TROPOCOLLAGEN MOLECULES in a FIBER 
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D4
Cat Hpx
Cat     Hpx
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GLOGERGRTGPAGAAGAR
FIGURE 6. STRUCTURAL SCHEMATIC ILLUSTRATING THE PROXIMITY OF 
TOOLKIT PEPTIDES II-8 AND II-44 WITHIN THE COLLAGEN FIBER 
 
